IDH1 and neoplasm: demonstrated that the occurrence of IDH1/2 mutation may inhibit the aggregation of effector T cells in tumor patients, while the use of IDH inhibitor can effectively increase the infiltration of these cells in tumors, suggesting that IDH1/2 may be a biomarker of immunotherapy.